DHA + AA Supplements for Premature Birth Development
What You Need to Know Before You Apply
What is the purpose of this trial?
This is a continuation study to the Omega Tots trial (NCT01576783). The purpose of this study is to follow-up with participants of the original study to determine the long-term effect a daily fatty acid dietary supplement taken during toddlerhood might have on children born preterm now that they are 8.5-10.5 years old.
Who Is on the Research Team?
Sarah Keim, PhD
Principal Investigator
Nationwide Children's Hospital
Are You a Good Fit for This Trial?
This trial is for children aged between 8 years and 6 months to 10 years and 6 months who were born prematurely and took part in the original Omega Tots study. Children under the care of child services during their eligibility period cannot participate.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Follow-up
Participants from the original Omega Tots trial are assessed for long-term effects of DHA+AA supplementation on cognitive and behavioral outcomes
Data Analysis
Data collected from the follow-up visit is analyzed to determine the long-term effects of supplementation
What Are the Treatments Tested in This Trial?
Interventions
- Docosahexaenoic Acid + Arachidonic Acid (DHA+AA)
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Sarah Keim
Lead Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator